· rebuilt nightly from public records
Signal Sheet
Cambrian BioPharma is a private pharmaceuticals company in New York, New York. It raised $123.8M in Jun 2026 and its filings name 11 officers. Everything below links to the record it came from.
Equity raise reported to the SEC, Jun 2026.
CapitalPick the companies and territory you sell to and get dated, sourced reasons like these for each one, ranked by who is most likely to buy now. Your list stays yours.
Want this matched to what you sell? Get early access to Pursuit Plans →The most recent events first, refreshed every night. Each links to the record it came from.
| When | What happened | Kind | Source |
|---|---|---|---|
| Jun 30, 2026 | Raised $123.8M in equity from 80 investors | Capital | SEC filing |
The roles that matter for a seller right now. Names on this page come from SEC filings or the company's own announcements. Contacts you find with a free trial are verified before you see them. How we source names
| Role | Contact | Source | Why they matter now |
|---|---|---|---|
| Executive Officer | James Peyer | SEC filing, Jun 2026 | Named officer in the filing; part of the buying group |
| Executive Officer | Juliette Han | SEC filing, Jun 2026 | Named officer in the filing; part of the buying group |
| Executive Officer | Mark Nuttall | SEC filing, Jun 2026 | Named officer in the filing; part of the buying group |
| Executive Officer | Ruth Thieroff-Ekerdt | SEC filing, Jun 2026 | Named officer in the filing; part of the buying group |
| Executive Officer | William DeVaul | SEC filing, Jun 2026 | Named officer in the filing; part of the buying group |
| Chief Technology Officer | Christian Angermeyer | SEC filing, Jun 2026 | Technology and tooling decisions |
| Chief Technology Officer | Maryanna Saenko | SEC filing, Jun 2026 | Technology and tooling decisions |
| Chief Technology Officer | Brenton L. Saunders | SEC filing, Jun 2026 | Technology and tooling decisions |
| Chief Technology Officer | Paul Farr | SEC filing, Jun 2026 | Technology and tooling decisions |
| Chief Technology Officer | Martin Gunhaga | SEC filing, Jun 2026 | Technology and tooling decisions |
| Chief Technology Officer | Lorin Van Nuland | SEC filing, Jun 2026 | Technology and tooling decisions |
Lakewave does the research, the stitching and the first draft with AI, so you spend your time selling.
Lakewave tracks raises, new leaders, hiring and filings across your accounts and territory, and tells you the day something changes.
Find the decision makers, get mailbox-verified addresses and an AI draft written for that account, which you review. Send from your own inbox with open and reply tracking and a follow-up sequence.
Which accounts to pursue, why now, who to reach and what to say, matched to your product and the buyers you sell to.
Every address Lakewave gives you is checked against Cambrian BioPharma's mail server before you see it. Guessed addresses bounce, and bounces are what push a sender's domain toward the spam folder, so one bad list can cost a rep weeks of deliverability. Lakewave shows how each address was confirmed and leaves out the ones it cannot verify.
Use it two ways. Look up the verified address you need for a call you are already planning. Or let Lakewave do the whole job: find the accounts with a reason to buy now, the right people and their addresses, and draft a first email for each person, so you are not stitching together data sources and research by hand.
Try it on Cambrian BioPharma with a free trial →| Headquarters | New York, New York, per the filing address |
| Industry group | Pharmaceuticals |
| Ownership | Private company |
| Raise history | $123.8M (Jun 2026) |
| Lakewave Rising | 15 · 1 kinds of evidence · rank in New York after sign-up |
Private-sector companies in the same industry group and state, ranked by Rising score.
Yes. Cambrian BioPharma reported a $123.8M equity raise to the SEC on Jun 30, 2026 with 80 investors.
The company's SEC filing, Jun 2026 names James Peyer (Executive Officer) among its officers.
New York, New York, per the address on its SEC filing.
Select the accounts and territory you sell to and get dated reasons for every company: new budget, new leaders, new hires, with who to reach and a first draft for each contact.
Start your free trialEvery account you select comes back scored by what changed this month, with the source for each fact.
Named officers from filings and announcements, each with an address verified against the mailbox. No bounces, no guessed patterns, no scraped profiles.
Lakewave writes a first email for each person, tailored to their role and company. You edit, approve and send it from your own mailbox.
A weekly note on what changed across your targets, so no account moves without you knowing.
Free trial · No credit card · Built from public records, refreshed nightly
Compiled from public records and refreshed nightly; last updated Nov 10, 2026. Facts are as the SEC, the company's careers page or the company's own announcements published them. Check the source before acting. See something wrong? Tell us and we will correct it.